Filing identity and reporting period
Important mismatch: The supplied filing is Oaktree Acquisition Corp.’s 2019 Form 10-K, not a filing by Hims & Hers Health, Inc. It covers the period from inception on April 9, 2019 through December 31, 2019; it does not provide a standalone fourth-quarter comparison. Oaktree was a blank-check company seeking a business combination, not an operating healthcare business.
Financial results and liquidity
- Revenue and operations: No operating revenue or operating business. Operating expenses were $710,080; net income was $1,147,262, primarily reflecting $1,857,342 of trust-account investment interest.
- Cash flow: Operating cash use was $241,682; investing cash use was $201.25 million, principally funds placed in trust; financing cash inflow was $203.0 million. Year-end cash outside the trust was $1,510,341.
- Assets and liquidity: Year-end trust investments were $203,107,342, and working capital was approximately $678,000. The filing also describes approximately $1.9 million of trust interest as available for specified withdrawals and taxes, subject to limits.
- Debt and obligations: No long-term debt and no outstanding working-capital loans at year-end. Current liabilities were $979,394, plus $7,043,750 of deferred underwriting commissions and $150,000 of deferred legal fees. The company paid an affiliate $10,000 monthly for office and administrative services.
- Profitability and margins: Operating margins are not meaningful because the company had no operating revenue. No comparable prior-year period is presented.
Material changes and unusual items
The company completed its IPO on July 22, 2019, selling 20.125 million units at $10 each and raising $201.25 million gross; it also raised approximately $6.03 million through a private placement of warrants. Most IPO proceeds were placed in trust. The filing reports $19,159,203 Class A shares subject to possible redemption as temporary equity and $5,000,009 of shareholders’ equity.
There is an apparent trust-balance presentation to reconcile: the financial statements show $203.1 million of trust investments and a separate $7.04 million deferred underwriting liability, while narrative text cites approximately $196.06 million after deferred underwriting fees.
Outlook, risks and contingencies
- Management expected available working capital and potential sponsor borrowing capacity to fund operations through the earlier of a business combination or one year from filing; sponsor financing was not committed.
- The company had until July 22, 2021—24 months after the IPO—to complete a business combination or redeem public shares and liquidate, subject to creditor claims and other terms.
- Key risks included failure to find or complete a suitable acquisition, redemption-driven cash constraints, dilution or debt financing, conflicts of interest involving Oaktree and its affiliates, and possible loss of trust assets to creditor claims. Warrants could expire worthless if no transaction closed.
- The filing discusses COVID-19 as a subsequent-event uncertainty that could disrupt the acquisition search or affect a future target; the impact was not determinable, and the financial statements were not adjusted.
- No material litigation was reported. Disclosure controls were assessed as effective; the filing did not include management’s internal-control assessment or an auditor attestation.
Important facts for investors to verify
- Confirm the filing belongs to Oaktree Acquisition Corp., not Hims & Hers Health, Inc.
- Reconcile the $203.1 million reported trust investments with the narrative’s approximately $196.06 million figure and deferred underwriting obligations.
- Verify the trust withdrawal limits, redemption terms, creditor protections, and July 22, 2021 business-combination deadline.
- Review potential sponsor conflicts, the 20% founder-share interest, warrant dilution and redemption provisions, and any later transaction or financing disclosures.